Newlink Genetics (NLNK) Posts Q3 Loss of 28c

Newlink Genetics (NASDAQ: NLNK) reported Q3 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $327 thousand versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Newlink Genetics (NLNK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• RCM Technologies (RCMT) Tops Q2 EPS by 17c